surmount-1 tirzepatide non-diabetic obesity trial (ZEPBOUND) Approved for Chronic Weight Management in Adults with ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Tirzepatide cuts diabetes risk by

Ozempic has joined that elite group where the brand name doesnt just sell the product its become synonymous with its entire category. Two-thirds of Americans now say they want to lose weight, Dan Frommer notes in his Consumer Trends deck for 2026

The most common adverse effects associated with therapeutic semaglutide use include gastrointestinal symptoms, which might theoretically occur more rapidly or intensely with direct venous administration

Which risk markers besides body weight does the post's cardiovascular table track

The risk of gastric ulcers and gastrointestinal bleeding is a well-established concern with NSAIDs, particularly with prolonged use, higher doses, or in patients over 65 years of age

Its on consumers to ensure that the pharmacy sending the drug is licensed in the state they live in